LR379

Interim study to examine the role of health insurance for biomarker testing and the use of biomarker testing in public and private payor markets

Back to Bill Detail
Print Friendly
LR379 Actions
Date Description Journal Vote
Apr 05, 2024 Referred to Banking, Commerce and Insurance Committee 1535
Mar 25, 2024 Referred to Executive Board 1250
Mar 25, 2024 Date of introduction 1249